51 patents
Page 2 of 3
Utility
Materials and methods for treatment of primary hyperoxaluria type 1 (PH1) and other alanine-glyoxylate aminotransferase (AGXT) gene related conditions or disorders
9 Aug 22
The present application provides materials and methods for treating a patient with one or more conditions or disorders associated with AGXT, both ex vivo or in vivo.
Ante Sven Lundberg, Samarth Kulkarni, Lawrence Klein, Hari Kumar Padmanabhan
Filed: 21 Feb 18
Utility
Allogeneic cell therapy of B cell malignancies using genetically engineered T cells targeting CD19
19 Jul 22
A population of genetically engineered immune cells (e.g., T cells), which express a chimeric antigen receptor (CAR) specific to CD19 and contain a disrupted TRAC gene, a disrupted B2M gene, or both, for use in treating a B cell malignancy.
Mark Benton, Tony Ho, Demetrios Kalaitzidis, Ewelina Morawa, Jonathan Alexander Terrett
Filed: 22 Apr 21
Utility
Compositions and methods for genomic editing by insertion of donor polynucleotides
17 May 22
The present disclosure provides donor polynucleotides, genome editing systems, methods, pharmaceutical compositions, and kits which correct or induce a mutation that causes Glycogen Storage Disease 1a in a genomic DNA (gDNA) molecule in a cell.
Troy Dean Carlo, Roman Lvovitch Bogorad
Filed: 18 Feb 21
Utility
Methods and compositions for treating cancer
22 Feb 22
Provided herein, in some embodiments, are methods and compositions (e.g., cell compositions) for the treatment of cancer.
Jonathan Alexander Terrett, Demetrios Kalaitzidis, Mary-Lee Dequéant, Zinkal Samir Padalia
Filed: 23 Apr 21
Utility
Materials and methods for engineering cells and uses thereof in immuno-oncology
28 Dec 21
Materials and methods for producing genome-edited cells engineered to express a chimeric antigen receptor (CAR) construct on the cell surface, and materials and methods for genome editing to modulate the expression, function, or activity of one or more immuno-oncology related genes in a cell, and materials and methods for treating a patient using the genome-edited engineered cells.
Jonathan Alexander Terrett, Demetrios Kalaitzidis, Lawrence Klein
Filed: 12 Apr 21
Utility
Materials and methods for engineering cells and uses thereof in immuno-oncology
21 Dec 21
Materials and methods for producing genome-edited cells engineered to express a chimeric antigen receptor (CAR) construct on the cell surface, and materials and methods for genome editing to modulate the expression, function, or activity of one or more immuno-oncology related genes in a cell, and materials and methods for treating a patient using the genome-edited engineered cells.
Jonathan Alexander Terrett, Demetrios Kalaitzidis, Lawrence Klein
Filed: 12 Apr 21
Utility
Materials and methods for engineering cells and uses thereof in immuno-oncology
7 Dec 21
Materials and methods for producing genome-edited cells engineered to express a chimeric antigen receptor (CAR) construct on the cell surface, and materials and methods for genome editing to modulate the expression, function, or activity of one or more immuno-oncology related genes in a cell, and materials and methods for treating a patient using the genome-edited engineered cells.
Jonathan Alexander Terrett, Demetrios Kalaitzidis, Lawrence Klein
Filed: 29 Sep 20
Utility
Universal donor cells
23 Nov 21
Genetically modified cells that are compatible with multiple subjects, e.g., universal donor cells, and methods of generating the genetically modified cells are provided herein.
Alireza Rezania, Rebeca Ramos-Zayas
Filed: 26 Apr 21
Utility
Materials and methods for treatment of Amyotrophic Lateral Sclerosis (ALS) and other related disorders
16 Nov 21
The present disclosure provides materials and methods for treating a patient with one or more conditions associated with SOD1 whether ex vivo or in vivo.
Ante Sven Lundberg, Samarth Kulkarni, Lawrence Klein, Hari Kumar Padmanabhan
Filed: 15 Jun 17
Utility
Materials and methods for engineering cells and uses thereof in immuno-oncology
9 Nov 21
Materials and methods for producing genome-edited cells engineered to express a chimeric antigen receptor (CAR) construct on the cell surface, and materials and methods for genome editing to modulate the expression, function, or activity of one or more immuno-oncology related genes in a cell, and materials and methods for treating a patient using the genome-edited engineered cells.
Jonathan Alexander Terrett, Demetrios Kalaitzidis, Lawrence Klein
Filed: 29 Jul 20
Utility
Materials and methods for engineering cells and uses thereof in immuno-oncology
5 Oct 21
Materials and methods for producing genome-edited cells engineered to express a chimeric antigen receptor (CAR) construct on the cell surface, and materials and methods for genome editing to modulate the expression, function, or activity of one or more immuno-oncology related genes in a cell, and materials and methods for treating a patient using the genome-edited engineered cells.
Jonathan Alexander Terrett, Demetrios Kalaitzidis, Lawrence Klein
Filed: 8 Jul 20
Utility
Universal donor cells
14 Sep 21
Genetically modified cells that are compatible with multiple subjects, e.g., universal donor cells, and methods of generating said genetic modified cells are provided herein.
Alireza Rezania, Rebeca Ramos-Zayas
Filed: 4 Sep 20
Utility
Universal donor cells
14 Sep 21
Genetically modified cells that are compatible with multiple subjects, e.g., universal donor cells, and methods of generating said genetic modified cells are provided herein.
Alireza Rezania, Rebeca Ramos-Zayas
Filed: 4 Sep 20
Utility
Materials and methods for treatment of Usher syndrome type 2A and/or non-syndromic autosomal recessive retinitis pigmentosa (ARRP)
14 Sep 21
The present application provides materials and methods for treating a patient with one or more of Usher Syndrome Type 2A and ARRP, both ex vivo and in vivo; materials and methods for editing an USH2A gene containing a guanine deletion at nucleotide position c.2299.
Mariacarmela Allocca, Akiko Noma, Abraham Scaria
Filed: 18 Jun 20
Utility
Universal donor cells
14 Sep 21
Genetically modified cells that are compatible with multiple subjects, e.g., universal donor cells, and methods of generating said genetic modified cells are provided herein.
Alireza Rezania, Rebeca Ramos-Zayas
Filed: 4 Sep 20
Utility
Universal donor cells
14 Sep 21
Genetically modified cells that are compatible with multiple subjects, e.g., universal donor cells, and methods of generating said genetic modified cells are provided herein.
Alireza Rezania, Rebeca Ramos-Zayas
Filed: 4 Sep 20
Utility
Universal donor cells
31 Aug 21
Genetically modified cells that are compatible with multiple subjects, e.g., universal donor cells, and methods of generating said genetic modified cells are provided herein.
Alireza Rezania, Rebeca Ramos-Zayas
Filed: 4 Sep 20
Utility
Materials and methods for treatment of hereditary haemochromatosis
10 Aug 21
Materials and methods for treating a patient with hereditary hemochromatosis (HHC), both ex vivo and in vivo, and materials and methods for modulating the expression, function, or activity of a haemochromatosis (HFE) gene in a cell by genome editing.
Roman Lvovitch Bogorad, Chad Albert Cowan, Ante Sven Lundberg
Filed: 16 Mar 17
Utility
Materials and methods for engineering cells and uses thereof in immuno-oncology
27 Jul 21
Materials and methods for producing genome-edited cells engineered to express a chimeric antigen receptor (CAR) construct on the cell surface, and materials and methods for genome editing to modulate the expression, function, or activity of one or more immuno-oncology related genes in a cell, and materials and methods for treating a patient using the genome-edited engineered cells.
Jonathan Alexander Terrett, Demetrios Kalaitzidis, Lawrence Klein
Filed: 15 Jun 20
Utility
Materials and methods for treatment of usher syndrome type 2A
27 Jul 21
The present application provides materials and methods for treating a patient with Usher Syndrome Type 2A, both ex vivo and in vivo; materials and methods for editing a USH2A gene in a human cell; materials and methods for editing an USH2A gene containing an IVS40 mutation; materials and methods for treating a patient with an USH2A gene containing an IVS40 mutation; and a method for deleting a sequence comprising an IVS40 mutation within a USH2A gene of a cell.
Albena Kantardzhieva, Akiko Noma, Abraham Scaria
Filed: 18 Jun 20